You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
News on molecular markers used to guide cancer treatment, assess prognosis, or detect relapse.
Patients are organizing themselves in groups based on the molecular features driving their tumors to better advocate for themselves, raise money, and influence research.
The changes include recommendations for first line immunotherapy in patients with high PD-L1 expression, and clarification on use of targeted therapies.
Results of a new study offer preliminary evidence that blood tests could select patients for treatment, and track response and resistance.
The so-called universal CDx approved by the FDA can gauge alterations across multiple genes associated with response to three lung cancer treatments.
Last week's buys of two oncology labs will allow Quest to provide new cancer diagnostic technologies to communities lacking major cancer research centers, it said.
Clinicians say they are using blood-based tests for patients who can't be biopsied as a way to get test results sooner, but implementing tests smartly and appropriately remains a challenge.
In head-to-head studies, a next-generation EGFR inhibitor and an ALK inhibitor beat their older counterparts in staving of cancer progression.
The first randomized study to show a PARP inhibitor benefits advanced breast cancer patients is also a sign of the expanding utility of BRCA testing in precision medicine.
The IHC test was used in clinical studies that led to Zykadia's approval last week as a first-line option for metastatic NSCLC patients with ALK rearrangements.
The expanded indication makes it a first-line option for metastatic non-small cell lung cancer patients with ALK rearrangements.